Referral Timing and Access to Advanced Therapies in Multiple Myeloma

In this segment, Dr. Ajay Nooka asks Dr. Noopur Raje to discuss how evolving data and expanding indications are influencing referral timing for advanced therapies in relapsed and refractory multiple myeloma. Dr. Raje highlights a shift toward earlier consideration of cellular and other advanced treatment approaches, emphasizing the importance of timely referral to preserve patient eligibility. The discussion explores changes in referral patterns from community practices and identifies ongoing barriers, including logistical challenges, misconceptions about toxicity, and concerns around care transitions. Dr. Raje also discusses the value of early consultation and co-management between academic and community centers, which can help optimize patient outcomes and support continuity of care. This segment underscores the importance of proactive referral strategies and collaborative care models in ensuring appropriate access to advanced therapies for patients with multiple myeloma.